Item 7.01. Regulation FD Disclosure.

On January 7, 2021, Sarepta Therapeutics, Inc. (the "Company") issued a press release and conducted an investor webcast presenting results from part one of Study 102 evaluating SRP-9001, the Company's investigational gene therapy for the treatment of Duchenne muscular dystrophy. Copies of the press release and the presentation are being furnished as Exhibits 99.1 and 99.2, respectively.

The information in this report furnished pursuant to Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit No.   Description
   99.1         Press release dated January 7, 2021: Sarepta Therapeutics Announces
              Topline Results for Part 1 of Study 102 Evaluating SRP-9001, its
              Investigational Gene Therapy for the Treatment of Duchenne Muscular
              Dystrophy
   99.2         Presentation dated January 7, 2021: Micro-dystrophin SRP-9001-102
              Top-line Clinical Data (Part One)
    104       The cover page from this Current Report on Form 8-K of Sarepta
              Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit
              101




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses